Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Provided By GlobeNewswire

Last update: Jul 23, 2025

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio (“Imagene”), of the combined company after the anticipated closing.